“we are fully on track on this and the study is coming this year.”

In context

“And as you said, the DMC regularly continue to endorse the tire progression and this happened also very recently. They check efficacy and safety. We remain blinded to the study. What I can tell you is that recently and there is a lot of data that tell us what is the bleeding rates with Eliquis. And in AFib study, it's a net to add maldexan helquis. And we remain blinded, but what the GMC is telling us and what we see in a blinded fashion in terms of bleeding rates, give us confidence that we are still very much on target to achieve the benefit that we hope showing that Eliquis and Murbexana similar in terms of efficacy, but that Malvexan can bring a benefit in reducing importantly the bleeding risks measured bleeding risk and also non-measured clinically relevant bleeding risks. These are we are fully on track on this and the study is coming this year. Chuck Triano: Thank you, Cristian Massacesi. Next question please. Operator: Absolutely. Our next question today comes from Courtney Breen with Bernstein. Please go ahead. Courtney Breen: Hi, guys. Thanks so much for taking the question today. I just wanted to double click on Eliquis question as well as on cost savings in 2026. I know your intention is to take more cost savings in the 2026 period. And so it would be great if you can kind of perhaps characterize those relative to what you're able to achieve through the year in 2025? And then on Eliquis, thanks for giving the details around kind of some of those 2026 dynamics. I think you made some additional comments on that '26 to '27 transition of a $1.5 to $2 billion further step down. Can you just help us understand kind of what is dri”